Tranilast (TR) could be investigated as a suitable anti-inflammatory and NLRP3 inflammasome inhibitor medication for the treatment of COVID-19 acute patients. Owing to its importance, our study was constructed for the determination of TR using a new, fast, sensitive, and reliable green spectrofluorimetric method. TR was quantified in this study by forming a complex with the acriflavine (AC) reagent. The reaction between TR and AC quenched the fluorescence of AC through the formation of an ion-association complex and the response was measured at 493 nm after excitation at 263 nm. It was observed that the quenching of the fluorescence of AC was linear ( = 0.9998) with the concentration of TR in the range of 1.0-15.0 μg mL. The limit of detection was 0.224 μg mL, and the limit of quantification was 0.679 μg mL. The fluorescence quenching mechanism was carefully studied and was confirmed to be able to analyze TR in its pure form and its prepared pharmaceutical dosage form. To validate the method, the international conference of harmonization (ICH) QR guidelines were followed. The statistical assessment of the proposed and comparison methods revealed no significant differences between them. Moreover, the green criteria of the method were evaluated and confirmed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361924 | PMC |
http://dx.doi.org/10.1039/d2ra02239g | DOI Listing |
Transl Psychiatry
January 2025
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Schizophrenia spectrum disorders (SSD) involve disturbances in the integration of perception, emotion and cognition. The corticolimbic system is an interacting set of cortical and subcortical brain regions critically involved in this process. Understanding how neural circuitry and molecular mechanisms within this corticolimbic system may contribute to the development of not only positive symptoms but also negative and cognitive deficits in SSD has been a recent focus of intense research, as the latter are not adequately treated by current antipsychotic medications and are more strongly associated with poorer functioning and long-term outcomes.
View Article and Find Full Text PDFNat Biotechnol
January 2025
Insilico Medicine AI Limited, Abu Dhabi, UAE.
We introduce a quantum-classical generative model for small-molecule design, specifically targeting KRAS inhibitors for cancer therapy. We apply the method to design, select and synthesize 15 proposed molecules that could notably engage with KRAS for cancer therapy, with two holding promise for future development as inhibitors. This work showcases the potential of quantum computing to generate experimentally validated hits that compare favorably against classical models.
View Article and Find Full Text PDFAdv Wound Care (New Rochelle)
January 2025
Division of Plastic Surgery, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Autologous adipose tissue grafting (AAG) can provide soft tissue reconstruction in congenital defects, traumatic injuries, cancer care, or cosmetic procedures; over 94,000 AAG procedures are performed in the United States every year. Despite its effectiveness, the efficiency of AAG is limited by unpredictable adipocyte survival, impacting graft volume retention (26-83%). Acellular adipose matrices (AAMs) have emerged as a potential alternative to AAG.
View Article and Find Full Text PDFBr Dent J
December 2024
Guy´s and St Thomas´ NHS Foundation Trust, London, UK.
Advice and guidance clinics allow one clinician to seek advice from another using the concept of telemedicine for the provision of real time care, including diagnosis, treatment planning and consulting. While advice and guidance (AAG) is more commonly used in medicine, the service is currently underutilised in dentistry. There is limited evidence regarding the patient outcomes of AAG services and the benefits and drawbacks of this service in dentistry.
View Article and Find Full Text PDFNature
December 2024
CatalYm, Munich, Germany.
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment. Yet, response rates are still limited, and tumour progression commonly occurs. Soluble and cell-bound factors in the tumour microenvironment negatively affect cancer immunity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!